Published in Clin Chem on February 01, 1985
In vivo and in vitro sodium pump activity in subjects with thyrotoxic periodic paralysis. BMJ (1991) 1.66
In vivo cation transport during short-term and long-term digoxin therapy. Br J Clin Pharmacol (1986) 0.87
Adverse drug reactions: definitions, diagnosis, and management. Lancet (2000) 16.12
Adverse drug reactions in a hospital general medical unit meriting notification to the Committee on Safety of Medicines. Br J Clin Pharmacol (1996) 4.50
Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem (1971) 3.34
Adenosine 3',5'-monophosphate as the intracellular mediator of the action of adrenocorticotropic hormone on the adrenal cortex. J Biol Chem (1967) 3.03
Randomized placebo-controlled trial of continuous positive airway pressure on blood pressure in the sleep apnea-hypopnea syndrome. Am J Respir Crit Care Med (2001) 2.68
Increased platelet aggregation responses to 5-hydroxytryptamine in patients taking chlorpromazine. Br J Clin Pharmacol (1975) 2.49
Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial. Lancet (2003) 2.47
Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials. BMC Med Res Methodol (2001) 2.33
Medication errors, worse than a crime. Lancet (2000) 2.24
A prescription for better prescribing. Br J Clin Pharmacol (2006) 2.24
Everest MS: Measurement of digoxin in plasma and its use in diagnosis of digoxin intoxication. Br Med J (1969) 2.08
Abnormal function of potassium channels in platelets of patients with Alzheimer's disease. Lancet (1998) 2.07
Mechanism of the antidepressant action of electroconvulsive therapy. Lancet (1978) 2.03
Inhibitory effect of chlorpromazine on the syndrome of hyperactivity produced by L-tryptophan or 5-methoxy-N,N-dimethyltryptamine in rats treated with a monoamine oxidase inhibitor. Br J Pharmacol (1971) 1.90
New deal for old hearts. BMJ (1991) 1.90
Rare diseases and orphan drugs. Br J Clin Pharmacol (2006) 1.83
Misuse of temazepam. BMJ (1991) 1.82
Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation (1999) 1.79
Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine. Nature (1976) 1.77
A 'same day' direct-access chest pain clinic: improved management and reduced hospitalization. QJM (1998) 1.77
Balanced prescribing. Br J Clin Pharmacol (2006) 1.74
The Measurement of Haemoglobin A1c by isoelectric focussing in diabetic patients. Diabetologia (1982) 1.62
Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis. Gut (1982) 1.60
Measurement of specific [3H]-ouabain binding to different types of human leucocytes. Br J Clin Pharmacol (1984) 1.56
Aortic stenosis, atherosclerosis, and skeletal bone: is there a common link with calcification and inflammation? Eur Heart J (2013) 1.55
Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled trial. Heart (2006) 1.55
Aortic valve calcification on computed tomography predicts the severity of aortic stenosis. Clin Radiol (2003) 1.52
Randomised controlled trial of continuous positive airway pressure and standard oxygen therapy in acute pulmonary oedema; effects on plasma brain natriuretic peptide concentrations. Eur Heart J (2002) 1.52
Electroconvulsive shock increases the behavioural responses of rats to brain 5-hydroxytryptamine accumulation and central nervous system stimulant drugs. Br J Pharmacol (1976) 1.48
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Lancet (2002) 1.46
Monitoring digoxin therapy: I. Plasma concentrations and an in vitro assay of tissue response. Br J Clin Pharmacol (1977) 1.44
Rational prescribing, appropriate prescribing. Br J Clin Pharmacol (2004) 1.43
Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man. Cardiovasc Res (2000) 1.43
Prescribing statins. Br J Clin Pharmacol (2005) 1.42
The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man. Br J Clin Pharmacol (1982) 1.40
Iatrogenic chest pain: a case of 5-fluorouracil cardiotoxicity. QJM (1996) 1.39
Hyperinsulinaemia in ischaemic heart disease: the importance of myocardial infarction and left ventricular function. Q J Med (1994) 1.39
Proceedings: An isolated perfused rat brain--some histological and metabolic features. Clin Sci Mol Med (1974) 1.38
In defence of polypharmacy. Br J Clin Pharmacol (2004) 1.38
Heart muscle disease related to HIV infection: prognostic implications. BMJ (1994) 1.37
Quipazine: its effects on rat brain 5-hydroxytryptamine metabolism, monoamine oxidase activity and behaviour. Neuropharmacology (1976) 1.35
5-HT1 agonists reduce 5-hydroxytryptamine release in rat hippocampus in vivo as determined by brain microdialysis. Br J Pharmacol (1989) 1.35
Further observations on the effect of repeated electroconvulsive shock on the behavioural responses of rats produced by increases in the functional activity of brain 5-hydroxytryptamine and dopamine. Psychopharmacology (Berl) (1977) 1.35
Plasma noradrenaline and adrenaline concentrations and dopamine-beta-hydroxylase activity in patients with shock due to septicaemia, trauma and haemorrhage. Q J Med (1978) 1.34
Cation transport functions in vitro in patients with untreated essential hypertension: a comparison of erythrocytes and leucocytes. Clin Sci (Lond) (1985) 1.34
Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation (2001) 1.32
Inhibition of 5-hydroxytryptamine-induced human blood platelet aggregation by chlorpromazine and its metabolites. Br J Pharmacol (1975) 1.31
Digitalis intoxication. Clin Sci (Lond) (1983) 1.29
Plagiarism - please don't copy. Br J Clin Pharmacol (2007) 1.29
Responses of isolated human basilar arteries to 5-hydroxytryptamine, noradrenaline, serum, platelets, and erythrocytes. J Neurol Neurosurg Psychiatry (1975) 1.28
Comparison of forearm vasodilatation to substance P and acetylcholine: contribution of nitric oxide. Clin Sci (Lond) (1997) 1.27
The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats. Neuropharmacology (1974) 1.26
(-)-Propranolol inhibits the behavioural responses of rats to increased 5-hydroxytryptamine in the central nervous system. Nature (1976) 1.26
Biomarkers and surrogate endpoints. Br J Clin Pharmacol (2005) 1.25
Changes in cardiac glycoside receptor sites, 86rubidium uptake and intracellular sodium concentrations in the erythrocytes of patients receiving digoxin during the early phases of treatment of cardiac failure in regular rhythm and of atrial fibrillation. Br J Clin Pharmacol (1979) 1.23
Serious verapamil poisoning: treatment with intravenous calcium gluconate. Br Med J (1978) 1.19
Clinical pharmacology--providing tools and expertise for translational medicine. Br J Clin Pharmacol (2008) 1.19
Thyroid disease and the heart. Heart (2000) 1.18
A sensitive radioenzymatic assay for adrenaline and noradrenaline in plasma. Br J Clin Pharmacol (1977) 1.17
A randomized, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 in moderate persistent asthma. Clin Exp Allergy (2011) 1.16
The epidemiology of carcinoid tumours in England and Scotland. Br J Cancer (1994) 1.15
A comparison of alpha 2-adrenoreceptor binding characteristics of intact human platelets identified by [3H]-yohimbine and [3H]-dihydroergocryptine. J Auton Pharmacol (1983) 1.15
ABC of monitoring drug therapy. Making the most of plasma drug concentration measurements. BMJ (1993) 1.13
ABC of monitoring drug therapy. Lithium. BMJ (1992) 1.13
The role of brain 5-hydroxytryptamine in the hyperactivity produced in rats by lithium and monoamine oxidase inhibition. Br J Pharmacol (1974) 1.13
What is a clinical trial? Br J Clin Pharmacol (2004) 1.13
The effect of diphenylhydantoin on brain 5-hydroxytryptamine metabolism and function. Neuropharmacology (1975) 1.13
Inhibition of 5-hydroxytryptamine-mediated behaviour by the putative 5-HT2 antagonist pirenperone. Neuropharmacology (1983) 1.12
Psittacosis masquerading as rheumatic fever. Br Med J (1978) 1.12
Drug interactions-information, education, and the British National Formulary. Br J Clin Pharmacol (2004) 1.12
The relationship between plasma catecholamines and severity of injury in man. J Trauma (1984) 1.11
Abnormal regulation of adenosine 3',5'-monophosphate and corticosterone formation in an adrenocortical carcinoma. J Clin Invest (1969) 1.11
A comparison of symptoms and intra-arterial ambulatory blood pressure during long term dual chamber atrioventricular synchronous (DDD) and ventricular demand (VVI) pacing. Br Heart J (1987) 1.11
Risk perception in drug therapy. Br J Clin Pharmacol (2006) 1.11
Metabolism of an oral tryptophan load. I: Effects of dose and pretreatment with tryptophan. Br J Clin Pharmacol (1980) 1.11
Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature (1980) 1.11
Enhanced 5-hydroxytryptamine-mediated behavioural responses in rats following repeated electroconvulsive shock: relevance to the mechanism of the antidepressive effect of electroconvulsive therapy. Psychopharmacology (Berl) (1979) 1.11
Enhancement of specific [3H]ouabain binding and ouabain sensitive 86rubidium influx in intact human lymphocytes by a dialysable factor in human and fetal calf serum. Clin Sci (Lond) (1987) 1.10
Plasma adrenaline and noradrenaline concentrations and dopamine-beta-hydroxylase activity in myocardial infarction with and without cardiogenic shock. Br Heart J (1979) 1.10
The characteristics of the binding of 12-alpha-[3H]-digoxin to the membranes of intact human erythrocytes: relevance to digoxin therapy. Br J Clin Pharmacol (1979) 1.10
Platelet aggregation and chlorpromazine therapy. Br J Clin Pharmacol (1978) 1.10
The use of colour vision measurement in the diagnosis of digoxin toxicity. Q J Med (1980) 1.09
Communicating information about drug safety. BMJ (2006) 1.08
A review of endocarditis in acquired immunodeficiency syndrome and human immunodeficiency virus infection. Eur Heart J (1995) 1.07